Table 3.
Association Between Baseline Covariates and Sustained Control of Human Immunodeficiency Virus (HIV) Load in an Early Infection Cohort
Covariate | Volunteers,a No. | ART-Free Follow-Up, PY | Viral Controllers, No. | Unadjusted Analysis | Adjusted Analysis | ||
---|---|---|---|---|---|---|---|
OR (95% CI) | P | OR (95% CI) | P | ||||
Estimated time of infection | |||||||
2005–2006 | 170 | 760.5 | 25 | Reference | … | ||
2007–2008 | 218 | 812.4 | 41 | 1.48 (.86–2.58) | .163 | … | |
2009–2011 | 202 | 570.2 | 41 | 1.82 (1.06–3.19) | .032 | … | |
Age at estimated time of infection | |||||||
<25 y | 160 | 544.8 | 38 | Reference | Reference | ||
≥25 y | 430 | 1598.4 | 69 | 0.58 (.37–.91) |
.016 | 0.64 (.39–1.06) |
.068 |
Sex | |||||||
Male | 351 | 1270.9 | 50 | Reference | Reference | ||
Female | 239 | 872.4 | 57 | 1.89 (1.24–2.90) |
.003 | 1.78 (1.12–2.84) |
.015 |
Risk group | |||||||
Discordant couple | 427 | 1522.8 | 71 | Reference | |||
MSM | 90 | 311.7 | 17 | 1.19 (.64–2.12) |
.556 | ||
Other heterosexual | 65 | 268 | 17 | 1.68 (.89–3.07) |
.097 | ||
Unknown | 8 | 40.8 | 2 | 1.41 (.20–6.35) |
.681 | ||
HLA-A*03, by sex | |||||||
Female | |||||||
No | 213 | 754.1 | 49 | Reference | |||
Yes | 26 | 118.3 | 8 | 1.33 (.51–3.18) |
.539 | ||
Male | |||||||
No | 325 | 1166.7 | 46 | 0.55 (.35–.85) |
.008 | ||
Yes | 26 | 104.2 | 4 | 0.57 (.16–1.59) |
.326 | ||
HLA-B*45:01 | |||||||
No | 499 | 1857.8 | 96 | Reference | Reference | ||
Yes | 91 | 285.5 | 11 | 0.62 (.3–1.16) |
.160 | 0.65 (.31–1.25) |
.222 |
HLA-B*58:02 | |||||||
No | 504 | 1819.2 | 96 | Reference | Reference | ||
Yes | 86 | 324 | 11 | 0.61 (.29–1.15) |
.148 | 0.53 (.25–1.04) |
.081 |
HLA-B*57 | |||||||
No | 535 | 1901.6 | 90 | Reference | Reference | ||
Yes | 55 | 241.6 | 17 | 2.02 (1.07–3.72) |
.026 | 1.90 (.98–3.58) |
.051 |
HLA-A*02:02 | |||||||
No | 535 | 1946.9 | 95 | Reference | |||
Yes | 55 | 196.3 | 12 | 1.32 (.64–2.55) |
.424 | ||
Baseline CD4+ T-cell count | 590 | 2143.2 | 107 | 1.13b (1.04–1.23) |
.002 | 1.09b (1.00–1.18) |
.058 |
HIV-1 subtype | |||||||
C | 273 | 929.7 | 38 | Reference | Reference | ||
A | 207 | 832.1 | 52 | 1.97 (1.24–3.17) |
.004 | 2.09 (1.27–3.49) |
.004 |
D | 81 | 278.4 | 15 | 1.43 (.72–2.74) |
.287 | 1.44 (.71–2.80) |
.292 |
Otherc | 29 | 102.9 | 2 | 0.46 (.07–1.64) |
.306 | 0.51 (.08–1.88) |
.383 |
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; MSM, men who report sex with men; OR, odds ratio; PY, person-years.
aData are for 590 volunteers with viral load, subtype, and HLA data available.
bData are the odds of viral control for every 100-cell increase in counts (ie, in the adjusted analysis, the odds of control increases 9% for every 100-cell increase in baseline CD4+ T-cell count).
cTwelve volunteers had subtype A1/D virus, 6 had subtype A1/C, 2 had subtype A1/A2/D, 2 had subtype CRF02_AG, 2 had subtype G, and 1 each had subtype A1/C/D, B, C/K, CRF11_CPX, or D/C.